• 1. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 2. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 3. An artificial blood vessel implanted three-dimensional microsystem for modeling transvascular migration of tumor cells?
  Xue-Ying Wang,Ying Pei,Min Xie,Zi-He Jin,Ya-Shi Xiao,Yang Wang,Li-Na Zhang,Yan Li,Wei-Hua Huang Lab Chip, 2015,15, 1178-1187
• 4. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 5. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Chloroquinolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Haloquinolines Chloroquinolines

Recent Advances in the Application of 2-CHLORO-6-FLUOROQUINOLINE-3-CARBONITRILE (CAS: 948291-71-2) in Chemical Biology and Pharmaceutical Research

The compound 2-Chloro-6-fluoroquinoline-3-carbonitrile (CAS: 948291-71-2) has recently emerged as a key building block in medicinal chemistry and drug discovery. This heterocyclic scaffold has attracted significant attention due to its versatile reactivity and potential biological activities. Recent studies have demonstrated its utility as a privileged structure for the development of novel therapeutic agents targeting various disease pathways.

Structural analysis reveals that the quinoline core of 2-Chloro-6-fluoroquinoline-3-carbonitrile provides an excellent platform for molecular modifications. The presence of both chloro and fluoro substituents at positions 2 and 6, respectively, along with the electron-withdrawing cyano group at position 3, creates unique electronic properties that facilitate diverse chemical transformations. This molecular architecture has been particularly valuable in the synthesis of kinase inhibitors and antimicrobial agents.

In recent medicinal chemistry applications, researchers have utilized 948291-71-2 as a precursor for developing potent EGFR (Epidermal Growth Factor Receptor) inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibited nanomolar inhibitory activity against mutant EGFR variants, showing promise for targeted cancer therapies. The structural flexibility of the quinoline core allowed for optimal positioning of pharmacophores in the ATP-binding pocket of the kinase domain.

Significant progress has also been made in antimicrobial drug development using this scaffold. The fluorine substitution at position 6 has been shown to enhance membrane permeability and bioavailability, while the chloro group at position 2 provides an excellent handle for further functionalization. Recent structure-activity relationship (SAR) studies have identified several derivatives with broad-spectrum activity against drug-resistant bacterial strains, including MRSA and ESBL-producing Enterobacteriaceae.

From a synthetic chemistry perspective, novel methodologies have been developed for the efficient preparation of 2-Chloro-6-fluoroquinoline-3-carbonitrile and its derivatives. A 2024 report in Organic Process Research & Development described an improved catalytic system for the cyanation step, achieving higher yields and better regioselectivity. These advancements have facilitated the scale-up production of this important intermediate for pharmaceutical applications.

The compound's potential in central nervous system (CNS) drug discovery has also been explored. Recent preclinical studies have shown that certain derivatives can cross the blood-brain barrier effectively, making them candidates for neurodegenerative disease treatments. Molecular modeling suggests that the planar quinoline structure contributes to favorable interactions with various CNS targets.

Looking forward, the unique properties of 2-Chloro-6-fluoroquinoline-3-carbonitrile position it as a valuable scaffold for fragment-based drug discovery. Its moderate molecular weight and balanced lipophilicity make it particularly suitable for developing lead compounds with optimized drug-like properties. Ongoing research is exploring its application in PROTAC (Proteolysis Targeting Chimera) design and covalent inhibitor development.

In conclusion, 2-Chloro-6-fluoroquinoline-3-carbonitrile (948291-71-2) continues to demonstrate significant potential across multiple therapeutic areas. Its versatile chemistry and favorable physicochemical properties make it an important tool in modern drug discovery efforts. As synthetic methodologies improve and our understanding of structure-activity relationships deepens, we anticipate seeing more drug candidates derived from this scaffold entering clinical development in the coming years.

• 95104-21-5(2-Chloroquinoline-3-carbonitrile)
• 79249-34-6(2-Chloro-7-methylquinoline-3-carbonitrile)
• 175204-94-1(2-Chloro-5-fluoro-3,8-dimethylquinoline)
• 351363-12-7(2-Chloro-5,8-dimethylquinoline-3-carbonitrile)
• 791644-48-9(2-chloro-5-fluoropyridine-3-carbonitrile)
• 136812-21-0(2-Chloro-8-methylquinoline-3-carbonitrile)
• 483287-37-2(2-Chloro-6-methylquinoline-3-carbonitrile)
• 132118-48-0(2-Chloro-7-fluoro-3-methylquinoline)
• 917747-10-5(2-chloro-5,7-dimethylquinoline-3-carbonitrile)
• 917750-50-6(2-chloro-6,8-dimethylquinoline-3-carbonitrile)